| E-Articles |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Health and Fitness > Back Pain > Diagnosing Osteoporosis - Solving The Broken Bones Mystery |
|
E-Articles - Diagnosing Osteoporosis - Solving The Broken Bones Mystery
Osteoporosis can occur when there is a loss of bone density and strength due to a variety of factors. Osteoporosis may be relat According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product ed to aging, certain types of medications, or other health related conditions. A diagnosis of osteoporosis is often made while d ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in iagnosing a fracture. It is important that osteoporosis is diagnosed early so that accurate and aggressive treatment management lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. can occur in order to reach the best outcome. Not only the financial cost but the health costs associated with a missed diagno here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe is of or even an inaccurate diagnosis of osteoporosis can be very high. The health consequences associated with an inaccurate o d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro r omitted diagnosis of osteoporosis can be seen for years to come. When initially diagnosed saying osteoporosis, your physician ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc must make the determination of whether the osteoporosis is a primary or secondary diagnosis. Primary osteoporosis means it tha easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi the diagnosis is a stand-alone diagnosis, meaning that there is no other health issue that is causing it. However, with a seco nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically ndary diagnosis of osteoporosis this means that there is another health condition which is causing the osteoporosis. Some other and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ health conditions which can lead to a secondary diagnosis of osteoporosis include conditions such as multiple myeloma, lymphoma ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi diabetes, Cushing’s disease, hyperthyroidism, osteogenesis imperfecta, and even Marfan's syndrome. The best medical test on to ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a day’s market for diagnosing osteoporosis is the DEXA scan. Considered the gold standard by many healthcare providers, the DEXA dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod scan is completely painless for patients and only takes about 10 minutes to perform. The scan uses limited amounts of radiation cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin to scan the bones of the wrist, the spine or the hip to assess general bone density. This can help your physician to make a de tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen initive diagnosis of osteoporosis as well as help your physician to determine if compared to others in your age and gender contr t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel ol group you have a higher risk of developing an osteoporosis related fracture. Diagnosing osteoporosis is a fairly straightfor ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust ward procedure that your general healthcare provider can handle. But even though it is an easy diagnosis to make, it is one tha y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products is critical to your overall health. So as you age and particularly if you are female or if you have other health conditions th . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de at put you at risk for osteoporosis, make sure that you work closely with your physician to make sure that you are appropriately elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip screened for osteoporosis. Diagnosing osteoporosis is one diagnosis that you can’t afford for your healthcare provider to miss tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Finding the Ideal Real Estate Agent - 5 Steps to Success
|